Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/0371, PI05/2044, RD16/0011/0012, RD16/0011/0009, RD16/0011/0004)
Received: 18 March 2020
Accepted: 31 August 2020
First Online: 11 September 2020
Ethics approval and consent to participate
: PEARL study is conducted according to the principles expressed in the Helsinki Declaration of 1983, and it was approved by the Research Ethics Committee of Hospital Universitario La Princesa (PI-518; March 28th, 2011). All patients included signed a written consent at study entry, and samples and data from patients included in this study were provided by the Biobank Biobanco Hospital Universitario de La Princesa (ISCIII B.0000763) and they were processed following standard operating procedures with the appropriate approval of the Ethics and Scientific Committees.
: Not applicable
: AF-O, AMO, SP, ET, LA, and MAGG declare that they have no competing interests.SC: reports personal fees from Abbvie, MSD, Lilly, Pfizer, Roche, Sanofi, Stada, UCB; nonfinancial support from Abbvie, BMS, Gebro, Lilly, MSD, Menarini, Novartis, Pfizer, Roche, UCB; and Academic help as Assistant professor of the Universidad Autonoma Madrid (UAM), for the course 2019–2020, from ROCHE-UAM.IG-A: reports grants from Instituto de Salud Carlos III, during the course of the study; personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; personal fees and non-financial support from Roche Laboratories; and non-financial support from MSD, Pfizer and Novartis, not related to the submitted work.